Johnson & Johnson has announced positive topline results from the Phase 3 MajesTEC-3 clinical study evaluating TECVAYLI® (teclistamab-cqyv) in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for patients with relapsed/refractory multiple myeloma who have received one to three prior lines of therapy. According to the company, the combination regimen demonstrated statistically significant improvements in progression-free survival and overall survival compared to standard of care regimens, as determined by an Independent Data Monitoring Committee. The overall safety profile was consistent with the known profiles of each monotherapy. The full results of the MajesTEC-3 study will be presented at a future major medical meeting and shared with health authorities.